These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

317 related articles for article (PubMed ID: 33713744)

  • 21. Bone Marrow-sparing Intensity Modulated Radiation Therapy With Concurrent Cisplatin For Stage IB-IVA Cervical Cancer: An International Multicenter Phase II Clinical Trial (INTERTECC-2).
    Mell LK; Sirák I; Wei L; Tarnawski R; Mahantshetty U; Yashar CM; McHale MT; Xu R; Honerkamp-Smith G; Carmona R; Wright M; Williamson CW; Kasaová L; Li N; Kry S; Michalski J; Bosch W; Straube W; Schwarz J; Lowenstein J; Jiang SB; Saenz CC; Plaxe S; Einck J; Khorprasert C; Koonings P; Harrison T; Shi M; Mundt AJ;
    Int J Radiat Oncol Biol Phys; 2017 Mar; 97(3):536-545. PubMed ID: 28126303
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and safety of nedaplatin-based concurrent chemoradiotherapy for FIGO Stage IB2-IVA cervical cancer and its clinical prognostic factors.
    Fujiwara M; Isohashi F; Mabuchi S; Yoshioka Y; Seo Y; Suzuki O; Sumida I; Hayashi K; Kimura T; Ogawa K
    J Radiat Res; 2015 Mar; 56(2):305-14. PubMed ID: 25428244
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Stromal PD-L1-Positive Regulatory T cells and PD-1-Positive CD8-Positive T cells Define the Response of Different Subsets of Non-Small Cell Lung Cancer to PD-1/PD-L1 Blockade Immunotherapy.
    Wu SP; Liao RQ; Tu HY; Wang WJ; Dong ZY; Huang SM; Guo WB; Gou LY; Sun HW; Zhang Q; Xie Z; Yan LX; Su J; Yang JJ; Zhong WZ; Zhang XC; Wu YL
    J Thorac Oncol; 2018 Apr; 13(4):521-532. PubMed ID: 29269008
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognostic relevance of programmed cell death-ligand 1 expression and CD8+ TILs in rectal cancer patients before and after neoadjuvant chemoradiotherapy.
    Chen TW; Huang KC; Chiang SF; Chen WT; Ke TW; Chao KSC
    J Cancer Res Clin Oncol; 2019 Apr; 145(4):1043-1053. PubMed ID: 30874889
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Influence of chemoradiation on the immune microenvironment of cervical cancer patients.
    Herter JM; Kiljan M; Kunze S; Reinscheid M; Ibruli O; Cai J; Niu L; Heßelmann I; Trommer M; Herter-Sprie GS; Köhler C; Marnitz S
    Strahlenther Onkol; 2023 Feb; 199(2):121-130. PubMed ID: 36251031
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of the survival outcome of neoadjuvant therapy followed by radical surgery with that of concomitant chemoradiotherapy in patients with stage IB2-IIIB cervical adenocarcinoma.
    Tian T; Gao X; Ju Y; Ding X; Ai Y
    Arch Gynecol Obstet; 2021 Mar; 303(3):793-801. PubMed ID: 33009996
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunologic impact of chemoradiation in cervical cancer and how immune cell infiltration could lead toward personalized treatment.
    Lippens L; Van Bockstal M; De Jaeghere EA; Tummers P; Makar A; De Geyter S; Van de Vijver K; Hendrix A; Vandecasteele K; Denys H
    Int J Cancer; 2020 Jul; 147(2):554-564. PubMed ID: 32017078
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Predictive relevance of PD-L1 expression combined with CD8+ TIL density in stage III non-small cell lung cancer patients receiving concurrent chemoradiotherapy.
    Tokito T; Azuma K; Kawahara A; Ishii H; Yamada K; Matsuo N; Kinoshita T; Mizukami N; Ono H; Kage M; Hoshino T
    Eur J Cancer; 2016 Mar; 55():7-14. PubMed ID: 26771872
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prediction of treatment response from the microenvironment of tumor immunity in cervical cancer patients treated with chemoradiotherapy.
    Someya M; Tsuchiya T; Fukushima Y; Hasegawa T; Hori M; Kitagawa M; Gocho T; Mafune S; Ikeuchi Y; Hirohashi Y; Torigoe T; Iwasaki M; Matsuura M; Saito T; Matsumoto Y; Sakata KI
    Med Mol Morphol; 2021 Sep; 54(3):245-252. PubMed ID: 33963949
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Distribution and Clinical Significance of CTLA-4, PD-1 and PD-L1 in Peripheral Blood of Patients with Small Cell Lung Cancer].
    Li H; Liu Y; Liu Y; Liu J; Zhao D; Wang Y; Cheng Y
    Zhongguo Fei Ai Za Zhi; 2017 Nov; 20(11):755-760. PubMed ID: 29167005
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Toripalimab combined with definitive chemoradiotherapy for locally advanced cervical squamous cell carcinoma patients (TRACE): A single-arm, phase I/II trial.
    Ou D; Cai R; Qi WX; Cui C; Cao L; Wang SB; Li H; Ma T; Miao Y; Xu C; Cai G; Cao WG; Gao YS; Chen JY; Xu HP
    Cancer Immunol Immunother; 2024 Oct; 73(12):244. PubMed ID: 39358560
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Combined chemoradiation of cisplatin versus carboplatin in cervical carcinoma: a single institution experience from Thailand.
    Tharavichitkul E; Lorvidhaya V; Kamnerdsupaphon P; Sukthomya V; Chakrabandhu S; Klunklin P; Onchan W; Supawongwattana B; Pukanhaphan N; Galalae R; Chitapanarux I
    BMC Cancer; 2016 Jul; 16():501. PubMed ID: 27435245
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Kinetics of Intratumoral Immune Cell Activation During Chemoradiation for Cervical Cancer.
    Dorta-Estremera S; Colbert LE; Nookala SS; Yanamandra AV; Yang G; Delgado A; Mikkelson M; Eifel P; Jhingran A; Lilie LL; Welsh J; Schmeler K; Sastry JK; Klopp A
    Int J Radiat Oncol Biol Phys; 2018 Nov; 102(3):593-600. PubMed ID: 30017792
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Chemoradiotherapy followed by consolidation chemotherapy involving paclitaxel and carboplatin and in FIGO stage IIIB/IVA cervical cancer patients.
    Mabuchi S; Isohashi F; Okazawa M; Kitada F; Maruoka S; Ogawa K; Kimura T
    J Gynecol Oncol; 2017 Jan; 28(1):e15. PubMed ID: 27958682
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Outcomes of chemoradiotherapy in cervical cancer--the Western Australian experience.
    Lim A; Sia S
    Int J Radiat Oncol Biol Phys; 2012 Mar; 82(4):1431-8. PubMed ID: 21640504
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prognostic value of PD-L1 expression on tumor cells combined with CD8+ TIL density in patients with locally advanced non-small cell lung cancer treated with concurrent chemoradiotherapy.
    Gennen K; Käsmann L; Taugner J; Eze C; Karin M; Roengvoraphoj O; Neumann J; Tufman A; Orth M; Reu S; Belka C; Manapov F
    Radiat Oncol; 2020 Jan; 15(1):5. PubMed ID: 31898519
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immune correlates of therapy outcomes in women with cervical cancer treated with chemoradiotherapy: A systematic review.
    Lakomy DS; Wu J; Lombe D; Papasavvas E; Msadabwe SC; Geng Y; Montaner LJ; Chiao E; Lin LL
    Cancer Med; 2021 Jul; 10(13):4206-4220. PubMed ID: 34117731
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-term follow-up results of a multi-institutional phase 2 study of concurrent chemoradiation therapy for locally advanced cervical cancer in east and southeast Asia.
    Kato S; Ohno T; Thephamongkhol K; Chansilpa Y; Cao J; Xu X; Devi CR; Swee TT; Calaguas MJ; de Los Reyes RH; Cho CK; Dung TA; Supriana N; Erawati D; Mizuno H; Nakano T; Tsujii H
    Int J Radiat Oncol Biol Phys; 2013 Sep; 87(1):100-5. PubMed ID: 23920390
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical efficacy of nedaplatin-based concurrent chemoradiotherapy for uterine cervical cancer: a Tohoku Gynecologic Cancer Unit Study.
    Kagabu M; Shoji T; Murakami K; Omi H; Honda T; Miura F; Yokoyama Y; Tokunaga H; Takano T; Ohta T; Shimizu D; Sato N; Soeda S; Watanabe T; Yamada H; Mizunuma H; Yaegashi N; Nagase S; Tase T; Sugiyama T
    Int J Clin Oncol; 2016 Aug; 21(4):735-740. PubMed ID: 26782958
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Chemoradiation-Induced Alteration of Programmed Death-Ligand 1 and CD8
    Lim YJ; Koh J; Kim S; Jeon SR; Chie EK; Kim K; Kang GH; Han SW; Kim TY; Jeong SY; Park KJ; Wu HG
    Int J Radiat Oncol Biol Phys; 2017 Dec; 99(5):1216-1224. PubMed ID: 29165286
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.